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Policy Forum
I
n 2005, we launched the Ethical, 
Social and Cultural (ESC) Program 
for the Grand Challenges in 
Global Health (GCGH) initiative, as 
described in the ﬁ  rst article in this 
series [1]. To identify key ESC issues, 
we conducted group discussions with 
investigators and program ofﬁ  cers from 
the GCGH projects, as well as interviews 
with developing world experts. Our 
approach is shown in Box 1.
This compilation of views from 
investigators and developing world 
experts is the ﬁ  rst description of ESC 
issues for the GCGH initiative. To our 
knowledge, it is also the ﬁ  rst analysis 
of ESC issues related to a large-scale 
science program in the developing 
world. In this article we outline the ESC 
issues identiﬁ  ed by these key informants.
What Is Already Known
As discussed in the ﬁ  rst paper of this 
series [1], the Human Genome Project 
set a standard for addressing ESC 
issues in large-scale science projects. 
Subsequent large-scale projects—such 
as the International HapMap Project 
[2] and National Nanotechnology 
Initiative [3]—contain ESC programs. 
Certain ESC issues surface across 
all three projects: community 
engagement, public engagement, 
beneﬁ  t sharing, economic impacts 
of technologies, cultural issues, and 
accessibility.
However, the GCGH ESC program 
is the ﬁ  rst large-scale science project 
focused exclusively on ESC issues 
related to the developing world [1]. 
The ESC issues identiﬁ  ed here should 
be of interest to the science and 
development community, especially 
to those focused on global health. 
Moreover, we hope our approach, 
and speciﬁ  cally the way we went about 
identifying ESC issues, will be useful 
to future large-scale science projects 
focused on the developing world.
Our Findings
The developing world experts 
identiﬁ  ed thirteen issues, discussed 
below and illustrated with direct 
quotations.
Community engagement. As 
described in greater detail in the 
third article in this series, community 
engagement is the process of working 
collaboratively with relevant partners 
who share a common goal and interests 
[4] . Many GCGH projects require 
extensive interactions with host 
communities, and both investigators 
and developing world informants 
stressed the need for appropriate 
community engagement.
For example, investigators 
introducing an intravaginal vaccine, 
conducting an observational study of 
severe cerebral malaria, or developing 
genetic strategies to control vectors 
will require adequate opportunities to 
listen to and understand the concerns 
and interests of the communities in 
which they work. Developing world 
experts stressed the need for early 
community engagement that involves 
the negotiations and deliberations 
necessary to make relationships 
between the investigators and 
community successful, respectful, 
and fair. “I think the most important 
lesson,” said Gita Ramjee, “is to 
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engage the community right from 
the beginning, making sure that their 
issues are addressed, making sure 
that they have representatives at the 
highest level and at the lowest level, 
and just effective communication 
and ongoing transparency between 
the researchers and the community.” 
Community engagement seeks to 
prevent exploitation [5,6] and involves 
attention to community authorization, 
permission, ownership, and legitimacy. 
It also requires representativeness 
of community leadership, assent 
among community members, and 
the community’s acceptance of new 
research strategies. As Dara Amar 
stated, “For sustainability of any 
program, it has to be owned by the 
community.”
Public engagement. Public 
engagement is a process that provides 
people with trustworthy information 
on key policy issues, elicits their input, 
and integrates it into decision making 
and social action. Several of the GCGH 
projects could require investigators 
to assess public perceptions of and 
demand for new technologies. 
Developing world experts stressed that 
public engagement will be important 
in the introduction of nutritionally 
enhanced foods and genetic strategies 
to control mosquito populations. Based 
on experience with the introduction 
of genetically modiﬁ  ed foods, GCGH 
investigators and developing world 
experts expect that some of the 
proposed studies will require well-
developed strategies for engaging 
the public, gauging their views and 
concerns, and incorporating their 
insights into the implementation of 
the intervention [7]. “You have to 
somehow get the information through 
the radio, newspapers and the TV,” said 
Florence Wambugu. “But sometimes, 
to get to the grassroots you have to 
get to the community through schools 
and churches. We have to get to the 
people.” Respondents recognized that 
public engagement is a two-way process.
Cultural acceptability. Some 
of the Grand Challenges involve 
the introduction of novel vaccine 
delivery systems, such as intravaginal 
or aerosolized vaccines, or the 
introduction of nutritionally enhanced 
foods that may differ (e.g., in color) 
from the varieties from which they are 
derived. In several cases, investigators 
identiﬁ  ed possible cultural barriers 
to adopting these technologies. 
Developing world experts noted that 
researcher awareness of cultural issues 
stemming from gender, religion, 
historical context, sexual practices and 
contraception use, and the existence 
of a “culture of science” inﬂ  uence 
whether people who need a technology 
will use it. Calestous Juma argued 
that “Every technology is viewed ﬁ  rst 
off in the context of how it might 
destroy the culture.” An anonymous 
participant linked this suspicion to 
colonialism: “Technology in Africa 
was introduced with colonization, 
and what the people of this continent 
were seeing is that colonial power will 
bring in only those technologies which 
were targeting natural resources…to 
sustain their own economies.” Gita 
Ramjee recommended: “Rather than 
shooting down the cultural beliefs, try 
to integrate the new technology in an 
appropriate way that doesn’t impinge 
on their cultural beliefs.”
Gender. Developing world experts 
identiﬁ  ed gender as a critical ESC issue. 
They stressed the challenges of working 
with vulnerable populations such as 
commercial sex workers, girls, and 
adolescents, encouraging researchers 
to make efforts to empower their 
subjects against abuse and exploitation 
through education, skills training, 
and counseling. “We’re researchers,” 
said Koleka Mlisana, who works with 
Figure 1. ESC Issues Identiﬁ  ed during Group Discussions (Seattle, Washington, November 2005)
GC, Grand Challenge; IP, intellectual property
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commercial sex workers in Durban, 
“but if you pick up an issue unrelated 
to your research topic like domestic 
violence what then is your obligation? 
Can we just turn our backs?”
The key informants noted that 
culturally engrained discrimination 
can leave women dependent on men, 
affecting their access to health care 
and contraceptives. Limited access 
to schooling for girls, in addition to 
a lack of discourse around the taboo 
topic of sex, prevents women from 
educating themselves about available 
reproductive health interventions. This 
discrimination, said informants, limits 
opportunities for women to ﬁ  ll gaps 
in the public health infrastructure, 
advocate for their needs, and make 
contributions in science and health. “I 
don’t think we’ve had strong enough 
advocates for women’s issues,” said 
Quarraisha Abdool Karim. “HIV...
acutely highlights gender differences—
greater burden of infection [in 
women], and also the North–South 
divide in that 90% of infections in 
women are really in developing 
countries and primarily in Sub-Saharan 
Africa.”
Post-trial obligations/beneﬁ  t 
sharing. Some GCGH investigators, 
particularly those proposing clinical 
We identiﬁ  ed ESC issues in the GCGH initiative through a 
sequential process of document analysis, group discussions with 
investigators and program staff, and interviews with experts 
from the developing world. We did not deﬁ  ne ESC issues for 
our respondents. Rather, we included in our analysis any issue 
that a respondent characterized as ethical, social, or cultural. 
This method produced a broad and inclusive set of ESC issues 
appropriate for a large-scale project with diverse needs.
In April and May 2005, we reviewed the proposals for the 
GCGH projects to identify ESC issues. Some of the proposals 
explicitly identiﬁ  ed ESC issues and provided speciﬁ  c strategies 
to address them. In our preliminary review, we identiﬁ  ed implicit 
ESC issues in the proposals. Each proposal was reviewed in 
depth by a member of our team, and we developed a common 
framework for ESC issues across the proposals.
In November 2005, at the GCGH kick off meeting in Seattle, 
Washington, we held group discussions to identify ESC issues 
from the standpoint of the investigators and program staff. 
We held 11 group discussions with a total of 168 investigators 
and program ofﬁ  cers (see Table S1). We asked them about 
gaps in knowledge with regard to the key ESC issues affecting 
the ultimate adoption of the technologies arising from their 
projects. We used our knowledge of the proposals to ask 
follow-up questions about speciﬁ  c issues in the groups. One 
member of our team took detailed notes of these sessions, and 
these data were analyzed using content analysis to identify 
key ESC issues by their relevance to particular Grand Challenge 
goals (Figure 1). We presented the listing of ESC issues to 
the GCGH investigators and program ofﬁ  cers at a member 
check, in a February 2006 activity report, in the June 2006 
ESC newsletter, and in a volume of ESC working papers at the 
October 2006 annual meeting. The list was well received in all 
contexts.
Between May and September 2006, as part of a larger study 
on the key forces inﬂ  uencing the development and adoption of 
health biotechnologies in the developing world, we conducted 
semi-structured, face-to-face interviews with experts from the 
developing world in academia, government, civil society, and 
the private sector. A few of these interviews were conducted 
in small groups of two or three or over the telephone. Of the 
99 interviewees we originally contacted based on input from 
GCGH project teams and staff, the ESC team, literature searches, 
and snowball sampling, 70 participated (see Table S2). While 
we received no response from a very small number of these 
invitees, most of those who were not enrolled were agreeable 
to being interviewed, but we had reached saturation in the 
data so did not proceed to interview them. Of the participants, 
21% were female. Participants represented the following World 
Health Organization regions: Africa, the Americas, the Eastern 
Mediterranean, South-East Asia, and the Western Paciﬁ  c. They 
came from government, academia, industry, and civil society. We 
asked participants to identify key ESC issues related to the GCGH 
technologies and then to comment on the ESC list generated by 
GCGH investigators and program ofﬁ  cers.
Interviews maintained ﬂ  exibility to pursue emergent issues, 
allowing informants to share information on the basis of 
personal insights and/or issues raised by other informants. Each 
key informant was provided in advance an overview of the GCGH 
program and a description of a number of relevant projects in 
order to promote informed discussion. The interviews took place 
in English, with Chinese interpreters in some instances. During 
the interview, participants were presented with the ESC issues 
identiﬁ  ed by the GCGH principal investigators and program 
staff, as shown in Figure 1. They were asked if the list captured 
the ESC issues in the GCGH initiative, if there were any issues 
missing, any listed that should not be, or any that needed to be 
modiﬁ  ed. Participants were also asked another set of questions 
about the factors (e.g., scientiﬁ  c, political, ﬁ  nancial) that facilitate 
or impede development or adoption of health biotechnology 
in the developing world, and this analysis is reported elsewhere 
[10]. We audiotaped, transcribed, and veriﬁ  ed the interviews, 
and then performed a content analysis of the data. All named 
informants gave permission to be quoted. Anonymous 
participants chose not to be linked to their quotations but 
agreed to be listed among the study participants.
Developing world experts conﬁ  rmed the ESC issues identiﬁ  ed 
by GCGH investigators and program ofﬁ  cers. However, they also 
provided important modiﬁ  cations to the list shown in Figure 1:
1. Almost all ESC issues were seen to cut across almost all GCGH 
goals, so the issues are no longer categorized by goal.
2. The issue “unintended promotion of unsafe sexual practices” 
was expanded to apply to other GCGH goals as “unintended 
consequences.”
3. Three other ESC issues were added: “gender,” “corruption,” 
and “accessibility.”
4. “Communication strategy” (i.e., the media strategy for the 
GCGH projects) was removed as a separate ESC issue since this 
was seen to be part of community and public engagement.
5. “North–South collaboration” became “collaboration” to reﬂ  ect 
the importance of South–South collaboration.
6. The ESC issue in Figure 1 entitled “Socio-economic and cost–
beneﬁ  t analysis of technologies” became the broader theme 
of “affordability,” which also incorporates ethical notions of 
equity.
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trials or observational research with 
a clinical focus, identiﬁ  ed issues 
related to beneﬁ  t sharing with the host 
communities and individual research 
participants. Developing world experts 
stated that exploitative histories of trials 
in developing countries complicate 
investigator–subject relationships. 
“Very little of the good results of all 
the research that has been done in 
sub-Saharan Africa ever gets back 
to the people who took part in the 
studies,” said Godfrey Tangwa. Most 
participants in the GCGH group 
discussions and key informant 
interviews felt that investigators had 
a responsibility to ensure continued 
treatment for their subjects after a trial 
ends. “If you provide somebody with 
contraceptives, then you can not just 
take that away when the trial is over,” 
said Gita Ramjee. “One needs to look 
at sustainability of an intervention 
that is provided, and you cannot start 
something and take it away later.”
Collaboration. Most of the GCGH 
projects involve collaborative 
research. Developing world experts 
emphasized the importance of capacity 
strengthening and collaboration 
between public and private sectors in 
the developing world, both to create 
sustainable science infrastructure 
and also to facilitate adoption of the 
resulting technologies. “International 
partnership is critical,” said M. K. Bhan, 
“not only to help ﬁ  nd solutions but 
stimulate a culture in these emerging 
economies where, in future they could 
increasingly make a contribution to 
that [biotechnology innovation].” 
The key informants emphasized 
the importance of balanced 
power dynamics in North–South 
collaboration. Finally, they emphasized 
the importance of South–South 
collaboration in developing regionally 
relevant technologies and sustainable 
economic beneﬁ  ts. N. K. Ganguly 
commented that developing countries 
should be both the producers and 
the consumers of relevant health 
technologies: “These products need to 
move from the developing countries 
if they are meant for developing 
countries.”
Role of civil society organizations. 
Both investigators and developing 
world informants highlighted the role 
of civil society and nongovernmental 
organizations (CSOs and NGOs) in 
working with communities, especially 
in developing countries, in the 
conduct of research and the uptake of 
technologies resulting from research 
ﬁ  ndings. The fourth paper in this series 
explores further the role of CSOs in 
research [8].
In particular, investigators 
recognized that some of the GCGH 
projects might attract the attention 
of CSOs, and they were eager to 
identify constructive partnerships. 
“My experience with sleeping sickness, 
malaria and others has been that 
they [NGOs and CSOs] have been 
crucially important,” said Niresh 
Bhagwandin. Developing world experts 
noted that CSOs can play a critical 
role in improving delivery of health 
interventions with already established 
networks and rural outreach efforts. 
However, according to one anonymous 
participant, partnerships with NGOs 
are only successful when the missions 
of the collaborating organizations 
are aligned: “For example, some of 
the religious groups, if you talk to 
them about HIV, they put such a 
negative view…that they do more 
harm than good.” Other limitations 
arise when the NGO is not an accurate 
representative of community needs. 
Mpoko Bokanga commented on: “The 
NGO community…interposing itself 
between the research and the farmers, 
pretending that they know the needs of 
the farmers better than the researcher.”
Affordability. Although GCGH 
investigators identiﬁ  ed “socio-economic 
cost–beneﬁ  t ratios” as an ESC issue, 
developing world experts expanded 
this theme into the broader notion 
of affordability. These experts saw 
affordability as an ethical issue rooted 
in the notion of equity. In populations 
living on less then a dollar a day, said 
participants, new technologies will not 
reach those in need unless they are 
donated or made affordable through 
subsidies.
“The cost really has to be affordable,” 
said Nares Damrongchai. “What if we 
were successful and really could deliver 
the solution in terms of technology 
solution, but the cost is too high 
and the people who really need the 
technology could not afford it…what 
kind of mechanism should we put in 
place to make the technology or the 
drug or the vaccine cheap enough to 
be affordable to people?”
Accessibility. Ensuring accessibility, 
said developing world experts, 
requires adequate equipment and 
facilities staffed by competent health 
care workers. Many cited poor 
infrastructure, especially in rural areas, 
as leading to power cuts that break 
cold chains, inadequate roads and 
transport that prevent patients from 
reaching clinics, or a lack of potable 
water to administer pills. “In terms of 
adopting technology,” said Rosemary 
Wolson, “particularly in countries with 
large rural populations, the question of 
access to healthcare altogether is one 
that’s very tricky.” Wolson described 
challenges such as “transport for 
people to get to hospital…refrigeration 
and cold chains…power cuts and 
roads.”
Regulatory issues. Both investigators 
and developing world experts stated 
that weak or absent intellectual 
property frameworks discourage 
researchers from taking the risks that 
lead to innovation. “If we want to join 
the kind of the development ladder 
we have to agree that the intellectual 
property is something that we have to 
respect,” said Yongyuth Yuthavong. 
Regulatory structures must be balanced 
between ensuring consumer safety and 
encouraging product development 
and distribution. The absence of 
functioning regulatory regimes in 
the developing world diminishes 
both consumer trust and regional 
collaboration. As R. A. Mashelkar 
stated, “We [India] don’t have a 
world class FDA [Food and Drug 
Administration]. We must build one 
progressively.” However, key informants 
said that for the world’s most dire 
health emergencies, the human right 
to access essential medicines must 
supersede concerns about intellectual 
property. Yuthavong continued: “In 
certain cases, for example cases of 
drugs for AIDS, we have to stand ﬁ  rm 
that we cannot really allow the price 
to be the international price, we have 
to somehow make it cheaper, because 
there’s a lot of people who are affected, 
and it’s a question of humanity.”
Collection, management, and 
storage of tissue samples. Many of the 
GCGH research projects require the 
collection, storage, and use of human 
tissue samples, and both investigators 
and developing world experts 
identiﬁ  ed obstacles inherent in those 
processes. During the group discussion 
sessions, investigators recognized that 
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in research is still poorly developed, 
particularly for international 
collaborative research projects. 
Developing world experts noted that 
the lack of guidelines can hamper 
research, while overly strict regulations 
can have the same effect. You Lin 
Qiao said: “[The] only difﬁ  culty is the 
regulatory, the government…They 
have very, very strict rules, so any...
biological material…you have to get 
it approved. Some experiments have 
to cancel or delay. It is not good for 
our research and scientiﬁ  c exchange.” 
Developing world experts also spoke 
to the need to develop guidelines that 
promote both scientiﬁ  c research and 
safety, and stressed that investigators 
must collaborate to enhance local 
research capacity to collect, manage, 
and store tissue samples [9]. An 
anonymous participant said: “If it 
[management, storage, and collection 
of tissue samples] can be done in South 
Africa and we have capacity to do it, 
we would do it…it’s much better than 
having foreigners coming in.”
Corruption and poor governance. 
Developing world experts cited 
corruption as an obstacle to accessing 
new technologies. In the media, 
Musthaque Chowdury identiﬁ  ed a 
tendency to “play into the hands 
of some vested interests,” with 
media coverage “not necessarily 
based on facts.” The concentration 
of government power and lack 
of transparency in the approval 
and regulatory processes of new 
technologies persuaded some 
developing world experts that public 
health came second to political 
expedience. Informants with 
experience in civil society said that 
collaboration with the public sector 
breaks down when government 
partners demand bribes. They also 
stated that poor governance starves 
public health initiatives of funds and 
staff. Commenting on the 2006 Kenyan 
administration, Judi Wakhungu said: 
“That’s the only time when we have a 
quorum in parliament, is when it is for 
their own beneﬁ  t. So their salaries are 
absolutely exorbitant now, and then 
they’ve been in power since January 
2003, and they have increased their 
remuneration three times.”
Unintended consequences. GCGH 
investigators identiﬁ  ed unintended 
promotion of unsafe sexual practices 
(e.g., increased exposure to sexually 
transmitted diseases due to perceived 
immunity as a result of GCGH vaccines 
or other technologies) as an ESC 
issue. Developing world experts saw 
broader application for this theme. 
Beyond the promotion of unsafe sex, 
participants identiﬁ  ed unintended 
consequences stemming from gaps 
in knowledge regarding clinical trial 
site selection, phase III clinical trial 
outcomes, the effects of genetically 
modiﬁ  ed organisms on biodiversity, 
local economy disruption, and drug 
resistance. Kiran Mazumdar-Shaw 
stated that unfamiliarity with the 
variables of a region when conducting 
clinical trials can “make a mess of 
the whole program.” An anonymous 
participant, discussing genetically 
modiﬁ  ed foods, stated: “Of course, I 
want to be sure that people are safe in 
eating these crops and that they’re not 
exposed to future disease problems. 
In curing one issue, we don’t want to 
create a public health disaster…and 
we must take whatever safeguards we 
can to prevent cross-pollination and 
pollution of a gene pool.” As R. A. 
Mashelkar stated, “In science, there 
are unintended consequences,” and 
their ethical implications cannot be 
underestimated.
Next Steps
We recognize that this study reﬂ  ects 
only a small sample of highly educated 
developing world informants. However, 
as leaders and experts in their ﬁ  elds, 
their understanding of these issues 
brings experience and perspective 
that adds tremendous value to our 
research. Additionally, we recognize 
the limitations of group discussions as a 
methodology which may not permit all 
participants to cover all relevant issues 
comprehensively.
Notwithstanding the inherent 
limitations of the methodology and 
composition of group discussions and 
interviews, this study ﬁ  lls a gap in the 
literature as the ﬁ  rst description of 
ESC issues in the GCGH initiative. 
This paper offers insights on thirteen 
ethical, social, and cultural issues, 
raising the unique perspectives of 
developing world experts. The ﬁ  ndings 
may help guide other researchers 
in global health focused on the 
developing world, allowing them to 
identify and address key potential 
ethical concerns with greater clarity 
and efﬁ  ciency. In the GSGH ESC 
program, we are now exploring many 
of the issues identiﬁ  ed in greater depth 
through global case studies.  
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